John M. Stulak, M.D., has a special interest in the surgical treatment of advanced heart failure, including the use of ventricular assist devices in heart transplantation.
- Ventricular assist device therapy
- Cardiac transplantation
- Mechanical circulatory support
- Arrhythmia surgery
- Valvular heart disease
- Coronary artery disease
Significance to patient care
Compared with medical therapy, ventricular assist device therapy has proved to significantly improve survival rates and quality of life in select patients with advanced heart failure. Significant progress has been made in pump technology innovation, refinement in the timing of therapy, patient selection, and implantation techniques, along with postoperative care and the prevention and management of device-related complications.
Currently, the majority of patients who are referred for implantation of a left ventricular assist device (LVAD) have end-stage heart failure with critical shock, or are experiencing a progressive decline and require intravenous medications to improve heart function. The severity of patient illness at the time of LVAD implementation directly affects surgical risks and long-term survival. So, targeting a population of patients who are less sick could potentially improve survival and reduce complications and adverse events.
- Program director, Cardiovascular Surgery Fellowship and Mechanical Circulatory Support and Cardiac Transplantation Fellowship, Mayo School of Graduate Medical Education, Mayo Clinic, 2015-present
- Director, Surgery Clerkship, Mayo Medical School, Mayo Clinic, 2014-present
- Chair, Surgery Peer Review Research Committee, Department of Surgery, Mayo Clinic, 2012-present
- Medical director, Cardiac Surgical Intensive Care Unit, Mayo Clinic, 2011-present